Spinal and peripheral modulation of gastric acid secretion and arterial pressure by neuropeptide Y, peptide YY, and pancreatic polypeptide in rats.
Spinal and peripheral modulation of pentagastrin-stimulated gastric acid secretion by the pancreatic polypeptide-fold (PP-fold) peptides, neuropeptide Y (NPY), peptide YY (PYY), and pancreatic polypeptide (PP), in urethane-anesthetized rats was evaluated. Neuropeptide Y, PYY, and PP (400 pmol) were administered via intravenous (IV) and intrathecal (IT) injections. The alpha 2 antagonist, yohimbine, was used to evaluate the role of the alpha 2 adrenergic receptors in the modulation of pentagastrin-stimulated gastric acid secretion by NPY, PYY, and PP. Peptide YY and PP (IV) rapidly increased pentagastrin-stimulated gastric acid secretion. Peptide YY and PP (IT) increased pentagastrin-stimulated gastric acid secretion following administration into the thoracic (T8-T10) region of the spinal cord. The alpha 2 adrenergic receptor antagonist, yohimbine, did not modify the increases in pentagastrin-stimulated gastric acid secretion following PYY and PP (IV or IT) administration. Neuropeptide Y (IT) decreased pentagastrin-stimulated gastric acid secretion. However, in the presence of alpha 2 adrenergic receptor blockade, pentagastrin-stimulated gastric acid secretion was potentiated by NPY (IT) administration. Therefore, the inhibitory effect of NPY (IT) on pentagastrin-stimulated gastric acid secretion required the activation of alpha 2 adrenergic receptors in the spinal cord of rats. Mean arterial blood pressure (MAP) was increased immediately following NPY and PYY (IV) administration. During the same time period, PP (IV) decreased MAP in anesthetized rats. Mean arterial blood pressure was rapidly increased by NPY and PYY (IT) in anesthetized rats. The increase in MAP following PYY (IT) was partially attenuated in the presence of yohimbine.(ABSTRACT TRUNCATED AT 250 WORDS)
Wager-Pagé
S A
SA
Faculty of Medicine, Department of Medical Physiology, University of Calgary, Alberta, Canada.
Rosenbaum
G
G
Veale
W L
WL
Davison
J S
JS
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology*; D005744:Gastric Acid / Q000378:metabolism*; D007275:Injections, Intravenous; D007278:Injections, Spinal; D008297:Male; D008845:Microinjections; D009478:Neuropeptide Y / Q000502:physiology; D009479:Neuropeptides / Q000008:administration & dosage / Q000502:physiology*; D010191:Pancreatic Polypeptide / Q000502:physiology; D019894:Peptide YY; D010455:Peptides / Q000008:administration & dosage / Q000502:physiology; D010525:Peripheral Nerves / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013116:Spinal Cord / Q000502:physiology*
D009478:Neuropeptide Y; D009479:Neuropeptides; D010455:Peptides; D019894:Peptide YY; D010191:Pancreatic Polypeptide